Evidence map›Paper›PMID 19424157›Full record

ArticleNature2009

Hypusine-containing protein eIF5A promotes translation elongation.

Preeti Saini, Daniel E Eyler, Rachel Green, Thomas E Dever

Open access · greenAbstract read
In one paragraph

Article in Nature, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 254 papers.

0numbers the graph read from it
0cells of the map it votes in
254citing papers in PubMed
13.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

254 citing papers in PubMed, 434 citations in OpenAlex.

  1. Review
  2. eIF5A and polyamines restrict mRNA levels in response to ribosome stalls.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. eIF5A coordinates the transcription and translation of its target genes.Cellular and molecular life sciences : CMLS · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Screening and Stability Validation of RT-qPCR Reference Genes inInternational journal of molecular sciences · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Capturing Translation in Action with Protein Synthesis Profiling.bioRxiv : the preprint server for biology · 2025
    Article
  14. Review
  15. Article
  16. Review
  17. mRNA translational control of regeneration.Current opinion in genetics & development · 2025
    Review
  18. Review
  19. Article
  20. Article

194 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Preeti SainiLaboratory of Gene Regulation and Development, NICHD, National Institutes of Health, Bethesda, Maryland 20892, USA.
Daniel E Eyler
Rachel Green
Thomas E Dever
Howard Hughes Medical Institute · USJohns Hopkins University · USNational Institutes of Health · US

Funding

Mechanism and Regulation of Eukaryotic Protein SynthesisZIAHD001010 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI DEVER, THOMAS E · 2009 to 2025
$29.4M
REGULATION OF EUKARYOTIC PROTEIN SYNTHESISZ01HD001010 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI DEVER, THOMAS E · 1995 to 2008
$2.6M
Howard Hughes Medical InstituteIntramural NIH HHS Z01 HD001010
6 · The paper itself

Abstract

Translation elongation factors facilitate protein synthesis by the ribosome. Previous studies identified two universally conserved translation elongation factors, EF-Tu in bacteria (known as eEF1A in eukaryotes) and EF-G (eEF2), which deliver aminoacyl-tRNAs to the ribosome and promote ribosomal translocation, respectively. The factor eIF5A (encoded by HYP2 and ANB1 in Saccharomyces cerevisiae), the sole protein in eukaryotes and archaea to contain the unusual amino acid hypusine (N(epsilon)-(4-amino-2-hydroxybutyl)lysine), was originally identified based on its ability to stimulate the yield (endpoint) of methionyl-puromycin synthesis-a model assay for first peptide bond synthesis thought to report on certain aspects of translation initiation. Hypusine is required for eIF5A to associate with ribosomes and to stimulate methionyl-puromycin synthesis. Because eIF5A did not stimulate earlier steps of translation initiation, and depletion of eIF5A in yeast only modestly impaired protein synthesis, it was proposed that eIF5A function was limited to stimulating synthesis of the first peptide bond or that eIF5A functioned on only a subset of cellular messenger RNAs. However, the precise cellular role of eIF5A is unknown, and the protein has also been linked to mRNA decay, including the nonsense-mediated mRNA decay pathway, and to nucleocytoplasmic transport. Here we use molecular genetic and biochemical studies to show that eIF5A promotes translation elongation. Depletion or inactivation of eIF5A in the yeast S. cerevisiae resulted in the accumulation of polysomes and an increase in ribosomal transit times. Addition of recombinant eIF5A from yeast, but not a derivative lacking hypusine, enhanced the rate of tripeptide synthesis in vitro. Moreover, inactivation of eIF5A mimicked the effects of the eEF2 inhibitor sordarin, indicating that eIF5A might function together with eEF2 to promote ribosomal translocation. Because eIF5A is a structural homologue of the bacterial protein EF-P, we propose that eIF5A/EF-P is a universally conserved translation elongation factor.

Indexed as

Eukaryotic Translation Initiation Factor 5AIndenesLysineMutationPeptide Chain Elongation, TranslationalPeptide Elongation FactorsPeptide Initiation FactorsPolyribosomesProtein Synthesis InhibitorsRecombinant ProteinsRNA-Binding ProteinsSaccharomyces cerevisiaeEukaryotic Translation Initiation Factor 5AhypusineIndenesLysinePeptide Elongation FactorsPeptide Initiation FactorsProtein Synthesis InhibitorsRecombinant ProteinsRNA-Binding Proteinssordarin

Identifiers

PMID19424157
PMCPMC3140696
OpenAlexW1983788160

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.